The Zurich-based Skribble, a specialist for electronic signatures, has completed a round of funding with an investment volume of EUR 10 million. The round is led by Acton Capital Partners from Munich, an international venture capital company that focuses on digital business models and sees strong revenue growth in Europe and North America. The Swiss […]
Tags : Robert von Rosen
The groupe. id has been acquired by German private equity firm Elvaston Capital Management. Based in La Chaux-de-Fonds and also present in Yverdon-les-Bains, the groupe.id is a renowed Swiss provider of enterprise resource planning software solutions. Founded in 1982, the Swiss group develops and delivers technological services with high added value, especially in terms of […]
Elvaston, an entrepreneur-led private equity firm, has sold its participation in Magnolia International to GENUI. The investment company has acquired a majority stake in Magnolia and will injects significant growth capital into the company. Magnolia is a Swiss based digital experience software company, developing and distributing a digital experience platform as well as a content […]
The Swiss pharmaceutical BioVersys has raised CHF 24.2 million in a first closing of its Series C round. This first closing was significantly oversubscribed by both existing and new investors from diverse geographies. The company intends to complete the Series C investment round by the end of 2022. The confidence of their investors and the […]
Cawood Scientific Limited, the UK based independent provider of analytical testing and sampling services for land-based industries, has tripled the size of its research business through the acquisition of Innovative Environmental Services (IES), an independent contract research organisation (CRO) located near Basel, Switzerland. Innovative Environmental Services (IES) services support the development, registration, and stewardship of pharmaceuticals, agrochemicals, biocides, and chemical products. […]
Private investment company Drs Investment sells 100 per cent of the shares in the Swiss software company Xelog to Prologistik Holding. The acquisition of Xelog, the Swiss logistics software specialist, is part of Prologistik’s strategy to build a pan-European logistics network and to expand further in other European countries. At the same time, Xelog’s customers […]
Walder Wyss acted as legal counsel to Dr. Wild & Co., the Swiss family-owned pharmaceutical manufacturer, on the sale of its Pharma business, including its product portfolio in Vitamin D and other well-known products, to Verfora an affiliate of Galenica Group (SIX Swiss Exchange: GALE), at the end of May 2021. On this transaction, the […]
Walder Wyss advises Boehringer Ingelheim. The team was led by Alexander Gutmans (Partner, Corporate/M&A and Venture Capital - pictured left) and Robert von Rosen (Partner, Corporate/M&A and Venture Capital). VISCHER advised NBE-Therapeutics and its shareholders in this transaction. The team was led by Matthias Staehelin (pictured right) with Vincent Reardon, Pauline Pfirter, Céderic Saladin (all Corporate) and Nadia Tarolli (Tax).
VISCHER is advising Noema Pharma in this transaction. The team is led by Matthias Staehelin (Corporate, pictured left). Walder Wyss advised Gilde Healthcare Partners, Polaris Partners, Invus Capital and BioMedInvest as investors. The team included Alexander Gutmans (Partner, Corporate/M&A and Venture Capital - pictured right),
The team included Alexander Gutmans (Partner, Corporate/M&A and Venture Capital - pictured), Robert von Rosen (Partner, Corporate/M&A and Venture Capital) and Karina Tschon (Associate, Corporate/M&A and Venture Capital).
